Diabetes medications
Browse the latest news, expert commentary, and educational content on diabetes medications.
-
»
A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
-
»
SGLT2 inhibitors: Key evidence and implications for clinical practice
-
»
Translating SGLT2 inhibitor cardiovascular evidence into practice
-
»
This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.
02-11-2021 | Semaglutide | At a glance | Article
A quick guide to the STEP trials
Read our round-up the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.
Image Credits
IDSC hub image/© 5second / stock.adobe.com, Scales and tape measure (graphic representing reducing size and weight)/© ktsdesign / stock.adobe.com, Blood pressure monitor/© pabijan / stock.adobe.com, John WIlding, Files/© adimas / stock.adobe.com, Man checking body fat (symbolic image with model)/© photophonie/stock.adobe.com, Carer chatting with elderly patient (symbolic image with models)/© Dean Mitchell/Getty Images/iStock, New Content Item/© Borislav / Getty Images / iStock, Medicine Matters branded image/© ipopba / Getty Images / iStock, Medicine Matters branded image/© fizkes / Getty Images / iStock